Maria Pia Morelli, MD, PhD, on Promising Efficacy of Sleeping Beauty TCR-T Therapy in Solid Tumors

“It's a very relevant treatment approach, not just for 1 or 2 patients - we can make a difference for a large number of patients... It's definitely relevant, it’s definitely specific, because it's something that is expressed on the cancer cell only on that patient so it's patient specific and very exciting in that sense. And we hope that we can bring immunotherapy also for cold diseases like colon cancer where immunotherapy isn’t currently used. With this approach, that should not be a limitation like we have encountered with immune checkpoint inhibitors. So,it definitely has large scale therapeutic implications.”

REFERENCE

Morelli MP, Negrao MV, Collinson-Pautz MR, et al. Safety and efficacy of Sleeping Beauty TCR-T cells targeting shared KRAS and TP53 mutations expressed by solid tumors in first-in-human phase 1 study. Presented at: 2023 ASCO Meeting; June 2-6; Chicago, Illinois. Poster #389